Zoetis Inc (NYSE:ZTS) insider Roman Trawicki sold 8,568 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $83.10, for a total transaction of $712,000.80. Following the completion of the transaction, the insider now owns 11,457 shares in the company, valued at $952,076.70. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Roman Trawicki also recently made the following trade(s):
- On Friday, February 23rd, Roman Trawicki sold 23,885 shares of Zoetis stock. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00.
Shares of Zoetis Inc (NYSE ZTS) opened at $84.35 on Thursday. Zoetis Inc has a 52 week low of $52.25 and a 52 week high of $85.54. The firm has a market cap of $41,100.00, a P/E ratio of 38.69, a P/E/G ratio of 1.89 and a beta of 0.97. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is currently 22.94%.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Chemical Bank purchased a new stake in Zoetis during the 4th quarter worth approximately $350,000. Cambridge Investment Research Advisors Inc. increased its position in shares of Zoetis by 27.9% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock valued at $1,288,000 after purchasing an additional 3,904 shares during the last quarter. Xact Kapitalforvaltning AB increased its position in shares of Zoetis by 9.8% in the 4th quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock valued at $5,051,000 after purchasing an additional 6,253 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Zoetis by 31.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock valued at $9,719,000 after purchasing an additional 32,149 shares during the last quarter. Finally, Dixon Hubard Feinour & Brown Inc. VA increased its position in shares of Zoetis by 106.2% in the 4th quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock valued at $1,807,000 after purchasing an additional 12,925 shares during the last quarter. 92.45% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently commented on ZTS. BMO Capital Markets set a $78.00 price objective on shares of Zoetis and gave the stock a “hold” rating in a report on Monday, January 22nd. Stifel Nicolaus restated a “buy” rating and issued a $86.00 price objective (up from $84.00) on shares of Zoetis in a report on Friday, February 16th. Cantor Fitzgerald set a $90.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a report on Thursday, February 15th. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price objective on the stock. in a report on Saturday, January 13th. Finally, Deutsche Bank upped their price objective on shares of Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus target price of $80.28.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.